Association of Family History with Cancer Recurrence and Survival in Patients with Gastric Cancer Journal of Clinical Oncology 2012 30:701-708 R2 Hwang.

Slides:



Advertisements
Similar presentations
Hereditary GI Cancer Syndromes: Keys to identify high risk patients
Advertisements

 DISCUSSION Number of resected lymph nodes in esophageal surgery has been previously discussed as for its probable impact on patients’ survival [4]. The.
National Oesophago–Gastric Cancer Audit Comparing local and national figures.
Lynch Syndrome and Colorectal Cancer Steven G. Proshan, M.D. Annapolis Colon and Rectal Surgeons Anne Arundel Medical Center November 8,
Impact of Lymph-Node Metastatic Site in Patients with Thoracic Esophageal Cancer Edited by: Kunisaki C., Makino H., Kimura J., Oshima T., Fujii S., Takagawa.
Pancreas Cancer Nimisha K. Parekh, MD, MPH
Management of Gastric Cancer Aviram Nissan, M.D. Department of Surgery Hadassah University Hospital Mount Scopus.
SHELBY ADDISON NEAL, MD MENTORS: WILLIAM T. CREASMAN, MD WHITNEY S. GRAYBILL, MD, MS Lymph-Vascular Space Invasion (LVSI) in Uterine Corpus Cancer What.
Is the BRAF V600E mutation useful as a predictor of preoperative risk in papillary thyroid cancer? The American Journal of Surgery.
62 years old man Main complaint: Back pain at night but not during the day Loss of appettite Weight loss.
Measures of disease frequency (I). MEASURES OF DISEASE FREQUENCY Absolute measures of disease frequency: –Incidence –Prevalence –Odds Measures of association:
Total Lesion Glycolysis by 18 F-FDG PET/CT a Reliable Predictor of Prognosis in Soft Tissue Sarcoma Ilkyu Han Musculoskeletal Tumor Center, Seoul National.
Management of GIST Dr Kwan Ming Wa Tuen Mun Hospital.
Giving Induction Radiation in Addition to Chemotherapy Is Not Associated with Improved Survival of NSCLC Patients with Operable Mediastinal Nodal Disease.
Gastric Cancer Prevention Luis S. Mon, M.D., F.A.C.S. Carlos A. Perurena, M.D.
Clinical Relevance of HER2 Overexpression/Amplification in Patients with Small Tumor Size and Node-Negative Breast Cancer Curigliano G et al. J Clin Oncol.
Colorectal cancer Khayal AlKhayal MD,FRCSC
Pier Luigi Filosso, MD University of Torino, Department of Thoracic Surgery The Impact of Adjuvant Chemotherapy in Pulmonary Large Cell Neuroendocrine.
Dr. LP Si Tseung Kwan O Hospital. Introduction CA stomach is the 4 th most commonly diagnosed malignancy worldwide 2 nd most common cause of cancer-related.
Meta-analysis of trials of radiotherapy in DCIS Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)
References 1.Salazar R, Roepman P, Capella G et al. Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J.
THE SIGNIFICANCE OF HISTOLOGICAL SUBSTAGING IN CURATIVE RESECTED T3 COLORECTAL CANCER Karl Mrak & Jörg Tschmelitsch Department of Surgery, Barmherzige.
Colorectal carcinoma Dr.Mohammadzadeh.
National Oesophago–Gastric Cancer Audit Key Findings from 2014 Annual Report and Progress Report Georgina Chadwick Clinical Research Fellow.
Dr Poonam Valand, Foundation Year Two Dr Anjan Dhar, Consultant Gastroenterologist COUNTY DURHAM AND DARLINGTON NHS FOUNDATION TRUST Early gastric cancer.
10 Minutes Talk 吳 華 席 Hua-Hsi Wu, MD OB/GYN, VGH-TPE Sep 08, 2008.
Multimodality therapy for locally advanced thymomas: a cohort study of prognostic factors from a European multicentric database Dr. GIOVANNI LEUZZI Department.
ACRIN 6685 Overview ACRIN 6685 A Multi-center Trial of FDG-PET/CT Staging of Head and Neck Cancer and its Impact on the N0 Neck Surgical Treatment in Head.
Background  Reports of long-term survivors (≥5 years) of locally advanced esophageal cancer (LAEC) have focused mainly on HRQL or GI symptoms  Only.
INCREASED EXPRESSION OF PROTEIN KINASE CK2  SUBUNIT IN HUMAN GASTRIC CARCINOMA Kai-Yuan Lin 1 and Yih-Huei Uen 1,2,3 1 Department of Medical Research,
A 58 years old man presents with melena. What would you ask him?
Colon Cancer. Multihit Concept Clinical Information Clinical Information 1. Patient identification a. Name b. Identification number c. Age (birth date)
The treatment of metastatic squamous cell carcinoma (SCCA) of the anal canal: A single institution experience P. Pathak, B. King, A. Ohinata, P. Das, C.H.
T Andre, E Quinaux, C Louvet, E Gamelin, O Bouche, E Achille, P Piedbois, N Tubiana-Mathieu, M Buyse and A de Gramont. Updated results at 6 year of the.
BASED ON PROTOCOL VERSION 1 SEPTEMBER 2012 A new study evaluating an investigational drug to treat patients with HER2-positive metastatic gastroesophageal.
Ductal Carcinoma in Situ with Microinvasion: Prognostic Implications, Long-term Outcomes, and Role of Axillary Evaluation Rahul R. Parikh, MD 1, Bruce.
on behalf of the ACOSOG Z4032 Investigators
Evidence for a Survival Benefit Conferred by Adjuvant Radiotherapy in a Cohort of 608 Women with Early-stage Endometrial Cancer O. Kenneth Macdonald 1,
Vulvar Cancer Women’s Hospital,School of Medicine Zhejiang University.
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of colorectal cancer: case report and literature review Alexandra.
Breast Cancer. Breast cancer is a disease in which malignant cells form in the tissues of the breast – “National Breast Cancer Foundation” The American.
Cmab might have therapeutic benefit in Japanese patients with KRAS p.G13D mutant colorectal cancer. Limitations of this study are its retrospective design.
Ki-67 index cutoff value of 1% is a valuable prognostic biomarker for pulmonary carcinoids based on this large cohort. Our data also provide strong evidence.
The impact of smoking on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB Nadine A. Jackson, Charles S.
Mamoun A. Rahman Surgical SHO Mr Osborne’s team. Introduction Blood transfusion: -Preoperative ( elective) -Intra/postoperative ( urgent) Blood transfusion.
Definition Signs & symptoms Treatment Root of the disease.
Surgery of colorectal metastasis in the Optimox 1 study. A GERCOR Study. N. Perez-Staub, G. Lledo, F. Paye, B. Gayet, M. Flesch, A. Cervantes, A. Figer,
Response-Guided Neoadjuvant Chemotherapy for Breast Cancer Gunter von Minckwitz, Jens Uwe Blohmer, Serban Dan Costa, Carsten Denkert, Holger Eidtmann Journal.
Adjuvant and Neoadjuvant Therapy in Non- Small Cell Lung Cancer Seminars in Oncology 2oo5;32 (suppl 2):S9-S15 Kyung Hee Medical Center Department of Thoracic.
2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial Aron Goldhirsch, Richard.
Adjuvant Chemotherapy for Non–Small-Cell Lung Cancer in the Elderly: A Population-Based Study in Ontario, Canada JOURNAL OF CLINICAL ONCOLOGY, VOLUME 30.
R3 정상완. Introduction  EGC : Tumor invasion is limited to the mucosa or submucosa, regardless of lymph node involvement.  Accumulated histopathological.
Sex-specific trends in lung cancer incidence and survival : a population study of cases 호흡기 내과 R3 조주희 Thorax 2011;66: Camilla M T Sagerup,
Eradication of Helicobacter pylori After Endoscopic Resection of Gastric Tumors Does Not Reduce Incidence of Metachronous Gastric Carcinoma Clinical Gastroenterology.
Should Elderly Patients Undergo Additional Surgery After Non-Curative Endoscopic Resection for Early Gastric Cancer? Long-Term Comparative Outcomes R3.
Lung Cancer in Never-Smokers from the Princess Margaret Cancer Centre 1 Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada;
THE IMPORTANCE OF STAGING AND PROGNOSTIC FACTORS IN CANCER CARE
Short-term outcome of neo-adjuvant chemotherapy
Prognostic significance of tumor subtypes in male breast cancer:
Results of Definitive Radiotherapy in Anal Canal Carcinoma
Prognosis of younger patients in non-small cell lung cancer
EMT inducing transcription factor SIP1: a predictive biomarker of colorectal cancer survival and recurrence? A Patel, R Sreekumar, R Bhome, KA Moutasim,
Tertiary cytoreductive surgery in recurrent epithelial ovarian cancer:
Department of Surgery, Taipei Veterans General Hospital Huang Kuo-Hung
Role of cytokeratins in the diagnosis and prognosis of the bladder cancer Giorgi Adeishvili MD Multiprofile clinic Consilium Medulla.
Published online September 20, 2017 by JAMA Surgery
Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer. A meta-analysis of two randomized trials E Mitry, A Fields,
NAACCR/IACR Combined Annual Conference 2019
Surgical resection of metachronous liver metastases
NSCLC: Staging and TNM classification
Presentation transcript:

Association of Family History with Cancer Recurrence and Survival in Patients with Gastric Cancer Journal of Clinical Oncology : R2 Hwang Jin Kyung

INTRODUCTION Gastric cancer is globally, –4 th most commonly diagnosed cancer. –2 nd most common cause or cancer motility. Family history of gastric cancer –Significantly associated with cancer development. –10.1~22.3% : have family history of the disease. –1~3% : cancer occur as part of an inherited cancer predisposition syndrome (hereditary non polyposis colorectal cancer, Li-Fraumeni syndrome, familial adenomatous polyposis, Peutz-Jeghers syndrome…)

INTRODUCTION Aim of this study –Effect of gastric cancer family history on the survival of patients with gastric cancer remains unclear! –Evaluate the effect of family history on the clinicopathologic characteristics and survival of patients with gastric cancer in a Korean population.

PATIENTS and METHODS Study population –National cancer center, a tertiary cancer center hospital, in Goyang, Korea. –Retrospective study : Aug ~ Dec –Korean ancestry. –Inclusion 20 years of age or older Histologically confirmed gastric adenocarcinoma Newly diagnosed cancer without previous treatment Gastrectomy with LN dissection in an curative intent Interviewed about family history and health behavior

PATIENTS and METHODS : Study population

PATIENTS and METHODS Personal characteristics and clinical data (1) –Demographic, health-related behavior Included age, sex, years of education, smoking/alcohol drinking status. –Clinicopathologic characteristics Included tumor location, size, differentiation, Lauren classification, gross type, depth of invasion, LN metastasis, stage at diagnosis, operation method, extent of LN dissection, adjuvant chemotherapy, H. pyroli infection status, multiplicity of tumor.

PATIENTS and METHODS Personal characteristics and clinical data (2) –Stage at diagnosis International Union Against Cancer/American Joint Committee on Cancer classification system (6 th edition). –In case of multiple synchronous gastric cancer, The lesion with deepest infiltration of the gastric wall  main lesion. The others  accessory lesion. The clinicopathologic charactoristics of the main lesion were used for analysis.

PATIENTS and METHODS Family history assessment –Self-reporting through an interview. –Classified according to first-degree or second-degree and cancer type. First-degree : parent, sibling, or offspring. Second-degree : aunt, uncle, niece, nephew, or grandparent. Cancer type : gastric cancer and all other cancer. If subjects had both first- and second-degree relatives  first-degree.

PATIENTS and METHODS Follow-up schedule –Advanced gastric cancer (T2 or more in TNM staging) First 3 years : every 3 months with physical exam, blood test every 6 months with abdomen CT. 2 years After that : biannually follow up. –Early gastric cancer (T1) Follow up at 3 months and then every 6 months for 5 years. Annual abdomen CT. –Annual endoscopy for 5 years in all patients. –Stage II~IV with LN metastasis : mainly received adjuvant CTx. Combination of fluoropyrimidine, platinum, irinotecan, and taxane.

PATIENTS and METHODS Statistical methods – Χ 2 test, Kaplan-Meier method, log-rank test, Cox proportional hazards model, SAS software (ver. 9.1) were used. –Two separate analysis were performed depending on the primary tumor stage (stage I~II vs. stage III~IV). –Terms of presenting outcome Disease-free survival (DFS) : time from surgery to tumor recurrence, occurrence of a new primary gastric cancer, or death of any cause. Recurrence-free survival (RFS) : time from surgery to tumor recurrence, death with evidence of recurrence, or occurrence of a new primary gastric cancer. Overall survival (OS) : time from surgery to death resulting from any cause.

RESULTS

RESULTS : Family history of study participants

RESULTS : Demographic and clinicopathologic characteristics

RESULTS : Effect of family history on the survival 84.4% vs 77.4% 87.0% vs 79.7% 90.8% vs 81.8%

RESULTS : Effect of family history on the survival of stage III~IV Family history was not associated with survival in stage I and II. Family history was associated with a significant reduction of cancer recurrence or mortality in stage III and IV.

RESULTS : Effect of family history on the survival of stage III~IV Significant associations between family history of gastric cancer in first-degree relatives and survival in patients with stage III and IV gastric cancer.

DISCUSSION Why a family history of gastric cancer affects patient survival? 1.Variability in adherence to surveillance monitoring. More likely to undergo regular gastric cancer screening. 2.Positive health-related behavior. Increased physical activity, quitting smoking, more sun-safe behavior, and positive dietary changes. 3.Genetic difference. Microsatellite instability (MSI) is associated with infrequent LN metastasis and lymph vessel invasion, intestinal type histology, and better overall prognosis.

DISCUSSION A major limitation of out study is… 1.Relied on self-reports of family history, without pathologic confirm. Reports of family history will always be clearer for those we know better and will be more uncertain as we extend to second-degree relatives. 2.Not include screening endoscopy history in our analyses. Might be different according to the family history and affect major outcomes. 3.Approximately 35% of patients were excluded because of uncertain H. pylori status H. pylori negative status is independent poor prognostic factor. 4.Did not perform genetic evaluation for MSI or CDH1 mutation.

A first-degree family history of gastric cancer is associated with improved survival after curative-intent surgery in patients with stage III or IV gastric cancer!